Walter Brendel Center of Experimental Medicine, Ludwig-Maximilians-University, Marchioninistrasse 15, Munich, Germany.
Neoplasia. 2010 Mar;12(3):254-63. doi: 10.1593/neo.91782.
The selenoenzyme glutathione peroxidase 4 (GPx4) has been described to control specific cyclooxygenases (COXs) and lipoxygenases (LOXs) that exert substantiated functions in tumor growth and angiogenesis. Therefore, we hypothesized a putative regulatory role of GPx4 during tumor progression and created transformed murine embryonic fibroblasts with inducible disruption of GPx4. GPx4 inactivation caused rapid cell death in vitro, which could be prevented either by lipophilic antioxidants or by 12/15-LOX-specific inhibitors, but not by inhibitors targeting other LOX isoforms or COX. Surprisingly, transformed GPx4(+/-) cells did not die when grown in Matrigel but gave rise to tumor spheroids. Subcutaneous implantation of tumor cells into mice resulted in knockout tumors that were indistinguishable in volume and mass in comparison to wild-type tumors. However, further analysis revealed a strong vascular phenotype. We observed an increase in microvessel density as well as a reduction in the number of large diameter vessels covered by smooth muscle cells. This phenotype could be linked to increased 12/15-LOX activity that was accompanied by an up-regulation of basic fibroblast growth factor and down-regulation of vascular endothelial growth factor A protein expression. Indeed, pharmacological inhibition of 12/15-LOX successfully reversed the tumor phenotype and led to "normalized" vessel morphology. Thus, we conclude that GPx4, through controlling 12/15-LOX activity, is an important regulator of tumor angiogenesis as well as vessel maturation.
硒酶谷胱甘肽过氧化物酶 4(GPx4)已被描述为控制特定的环氧化酶(COX)和脂氧合酶(LOX),这些酶在肿瘤生长和血管生成中发挥着重要作用。因此,我们假设 GPx4 在肿瘤进展过程中可能具有调节作用,并创建了诱导性破坏 GPx4 的转化鼠胚胎成纤维细胞。GPx4 失活在体外迅速导致细胞死亡,这可以通过亲脂性抗氧化剂或 12/15-LOX 特异性抑制剂来预防,但不能通过针对其他 LOX 同工酶或 COX 的抑制剂来预防。令人惊讶的是,当在 Matrigel 中生长时,转化的 GPx4(+/-)细胞不会死亡,而是形成肿瘤球体。将肿瘤细胞皮下植入小鼠中会导致 knockout 肿瘤,与野生型肿瘤相比,其体积和质量没有区别。然而,进一步的分析显示出强烈的血管表型。我们观察到微血管密度增加,以及平滑肌细胞覆盖的大直径血管数量减少。这种表型可能与 12/15-LOX 活性的增加有关,同时伴随着碱性成纤维细胞生长因子的上调和血管内皮生长因子 A 蛋白表达的下调。事实上,12/15-LOX 的药理学抑制成功地逆转了肿瘤表型,并导致“正常化”的血管形态。因此,我们得出结论,GPx4 通过控制 12/15-LOX 活性,是肿瘤血管生成以及血管成熟的重要调节剂。